Agent is idle (waiting for messages). agent_id: e9b74ede-e403-4321-a241-bedf2d88aa5b, agent_type: code-review, status: idle, description: Blind review of PDF, elapsed: 532s, total_turns: 1, model: gpt-5.6-sol

[Turn 0]
I cannot write the requested report file in this environment, so the full review is provided below.

**Accept probability:** [INFERRED] 15%  
**Verdict:** Reject  
**Arm naming:** [INFERRED] Only partly defensible. RANDOM and CENTROID are honest; ANATOMY-V1/V2 are adequately qualified; ENVELOPE is oversold as being “within” or “restricted to” retinal tissue; COVER describes an intended behavior that the implemented arm did not deliver.

**Three strongest reasons to reject:**
1. [INFERRED] H2 is not directly tested; the paper incorrectly treats failure to differ from RANDOM as proof that an anatomy arm cannot exceed ENVELOPE.
2. [INFERRED] “Location Beats Shape” is not identified because shape, mask ratio, context size, loss slots, and collation all change together, with only one pretraining run per policy.
3. [MEASURED] The PDF contradicts itself about whether COVER stopped at epoch 73 or reached epoch 100, whether later probes are pending or reported, and which runs are valid.

# 1. SUMMARY

[MEASURED] The paper compares six masking policies for continued I-JEPA pretraining on retinal OCT, all forked from one epoch-25 checkpoint and evaluated for glaucoma classification on the same FairVision test set of 3,000 volumes.

[MEASURED] RANDOM places ordinary rectangular targets without image guidance. ENVELOPE uses a retinal segmentation model to place rectangles near retinal tissue. CENTROID locates a band using an intensity-weighted centroid without a segmentation model. ANATOMY-V1 and ANATOMY-V2 grow irregular targets from a segmentation score map. COVER attempts to maximize covered anatomy while retaining a configured visible-tissue fraction.

[MEASURED] The central reported observations are that ENVELOPE exceeds RANDOM by +0.0120 AUC at epoch 50, CENTROID exceeds RANDOM by +0.0109 at epoch 100, and ANATOMY-V2 is only +0.0013 over RANDOM at epoch 50. The paper consequently argues that coarse location guidance helps, but greater anatomical precision does not.

[MEASURED] The paper supplements this comparison with delivered-mask measurements, subgroup analyses, numerical-precision re-probes, label-efficiency experiments, operating-point results, attribution analyses, and disclosure of a collation defect affecting COVER.

[INFERRED] The potentially valuable contribution is not a new masking architecture but a negative empirical result: segmentation-derived anatomical precision did not outperform simpler location biases in this particular experiment.

# 2. NAMING AND FRAMING

## RANDOM

[MEASURED] RANDOM uses stock I-JEPA rectangles placed uniformly without consulting image content.

[INFERRED] This name is descriptive and defensible.

## ENVELOPE

[MEASURED] The method section calls this arm “ENVELOPE (random-within-retina)” and repeatedly describes it as placing rectangles “on tissue” or “restricting targets to retinal tissue.”

[MEASURED] Table 2 reports mask purity of 43.5% for ENVELOPE.

[INFERRED] The name ENVELOPE itself is defensible if it denotes placement relative to a predicted retinal envelope. The parenthetical “random-within-retina” and the stronger prose claims are not: a mask with 43.5% purity is not literally restricted to retinal tissue. It is more accurately described as retina-biased placement or center placement within a retinal envelope.

[MEASURED] The paper clearly states that ENVELOPE uses MIRAGE predictions rather than ground-truth annotations.

[INFERRED] It therefore does not falsely imply access to ground-truth labels, but its framing overstates how completely it avoids background.

## CENTROID

[MEASURED] CENTROID uses a per-column intensity-weighted row centroid, no segmentation model, and no ground-truth annotations.

[INFERRED] This is an unusually clear and honest name. It describes the actual statistic rather than flattering the result.

[MEASURED] Table 8 unexpectedly renames the same arm INTENSITY.

[INFERRED] That unexplained renaming is an internal presentation defect. It does not oversell the method, but it makes the arm inventory less auditable.

## ANATOMY-V1 and ANATOMY-V2

[MEASURED] These arms grow connected components on the MIRAGE score map; V2 additionally bridges diagonal adjacency. ANATOMY-V2 achieves 97.3% mask purity in Table 2.

[INFERRED] “ANATOMY” could initially suggest ground-truth anatomy, but the method immediately identifies the trained segmentation model and does not claim annotation access. Given the reported purity, the broad name is defensible. The V1/V2 suffixes are opaque, but not materially misleading.

## COVER f=.21

[MEASURED] COVER is named for a greedy policy intended to cover anatomy subject to a visible-tissue floor.

[MEASURED] The disclosed defect means its targets are shortened after placement. The independent sweep reports 73.1% delivered anatomy coverage for COVER versus 77.6% for ENVELOPE, even though COVER was designed to cover more.

[INFERRED] As a name for the intended sampler, COVER is understandable. As a name for the experimental treatment actually delivered, it is misleading: the arm did not realize aggressive coverage. The paper should consistently call it a defective coverage-seeking arm rather than letting “COVER” imply that the intended intervention occurred.

## Overall naming judgment

[INFERRED] The naming is only partly defensible. RANDOM, CENTROID, and the qualified ANATOMY names are acceptable. ENVELOPE’s surrounding “within-retina” framing overstates its measured purity, while COVER names an unrealized capability. These two labels make the experimental ladder look cleaner and more anatomically ordered than the delivered interventions were.

# 3. INTERNAL CONSISTENCY

## Numerical agreement

[MEASURED] The principal abstract values agree with the main tables: ENVELOPE’s epoch-50 difference is +0.0120 with interval [+0.0068, +0.0173]; CENTROID’s epoch-100 difference is +0.0109 with interval [+0.0057, +0.0160]; ANATOMY-V2’s epoch-50 difference is +0.0013 with interval [−0.0055, +0.0082]; and COVER’s reported epoch-100 difference is −0.0168 with interval [−0.0233, −0.0105].

[MEASURED] The subgroup values in the abstract also agree with the appendix, including the mild-severity gain of +0.0137 and the statement that only the white race subgroup’s interval excludes zero.

## COVER timeline contradiction

[MEASURED] Section 4 says COVER “was deliberately halted at epoch 73.”

[MEASURED] Table 1 nevertheless reports COVER values at epochs 75 and 100. Section 5 says it was continued “to the full horizon,” fell to 0.8577, and ended −0.0168 below RANDOM.

[MEASURED] Section 6 then says COVER was “deliberately halted before epoch 100,” that later probes are pending, and that the paper draws no endpoint conclusion.

[MEASURED] Table 3 again lists COVER probes at epochs 75 and 100.

[INFERRED] These accounts cannot all be true. This is not a minor wording problem: it determines whether one of the abstract’s headline negative results exists, is valid, or is pending.

## Precision contradiction

[MEASURED] The Table 1 caption says no fp32 RANDOM null exists at epoch 75 and therefore the COVER epoch-75 difference is matched only on epoch.

[MEASURED] Table 12 reports an fp32 RANDOM result at epoch 75.

[MEASURED] The main text also states that all COVER contrasts are matched on both epoch and precision.

[INFERRED] The caption appears stale, and the claim that all contrasts are precision-matched disagrees with the caption as printed.

## Probe inventory contradiction

[MEASURED] The contributions describe a single evaluation protocol over 21 frozen probes, while the subgroup analysis repeatedly states that it uses 22 valid probes.

[MEASURED] Appendix C refers to “four retracted coverage probes,” while Table 3 labels the four retracted rows as RANDOM.

[INFERRED] A reader cannot reconstruct a unique, authoritative inventory of valid probes from the PDF.

## H1

[MEASURED] H1 is ENVELOPE greater than RANDOM, and the paper reports direct paired contrasts at epochs 50, 75, and 100 whose intervals exclude zero.

[INFERRED] H1 is supported as a fixed-run observation on these stored test predictions. It is not established as a reproducible policy effect because each encoder continuation was run once.

## H2

[MEASURED] H2 is that the anatomy arms exceed ENVELOPE.

[MEASURED] The paper does not report the required ANATOMY-V2-versus-ENVELOPE paired contrast. Instead, it argues that because ANATOMY-V2 does not separate from RANDOM while ENVELOPE does, ANATOMY-V2 cannot exceed ENVELOPE.

[INFERRED] That inference is statistically invalid. Failure to reject ANATOMY-V2 equals RANDOM is not evidence that ANATOMY-V2 is below ENVELOPE. H2 is unsupported, not directly refuted. Moreover, ANATOMY-V1 has only an epoch-30 probe and does not participate in the matched comparison used to discuss the plural “anatomy arms.”

## H3

[MEASURED] H3 states that any benefit is due to anatomical targeting rather than changes in mask area, target count, or context size.

[MEASURED] Section 5.2 is instead titled “H3: it is not anatomical targeting.” It reports a descriptive Spearman correlation of 0.00 over four rectangle policies and explicitly acknowledges that the anatomy comparison changes mask ratio, context size, loss slots, and collation simultaneously.

[INFERRED] H3 is not causally tested. The reported analysis argues descriptively against it but cannot distinguish anatomical targeting from incidental geometry. The hypothesis should be labeled unresolved or descriptively unsupported, not treated as settled.

## Severity-ordering contradiction

[MEASURED] Section 5.3 says all three severity intervals exclude zero and therefore “the ordering is resolved rather than a point-estimate artefact.”

[MEASURED] The abstract says the gains are not separated from one another, and Appendix C explicitly says the paper did not test paired differences between severity strata and that the ordering is descriptive only.

[INFERRED] The appendix and abstract give the statistically correct interpretation. Individual within-stratum intervals excluding zero do not establish an ordering between stratum gains.

## Further stale statements

[MEASURED] Appendix J says the subgroup audit contains no sensitivity analysis at a fixed clinical specificity.

[MEASURED] Appendix I and Table 9 report subgroup sensitivity changes at a validation-selected specificity target.

[MEASURED] The paper claims that one script prevents disagreement among tables, figures, and prose.

[INFERRED] The contradictions above directly undermine that assurance.

# 4. CLAIM CALIBRATION

## “Guidance helps”

[MEASURED] ENVELOPE and CENTROID each exceed RANDOM at the three reported matched epochs, with all six paired bootstrap intervals excluding zero.

[INFERRED] This is supported as a description of these particular trained encoders and test score vectors. It is too categorical as a general method claim because pretraining variance is completely unmeasured and the test split informed policy, checkpoint, and analysis choices.

## “Anatomical precision does not help” and “Location Beats Shape”

[MEASURED] ANATOMY-V2 differs from the rectangle arms in delivered mask ratio, context retained, loss slots, and collation. The paper itself says the comparison is not identified for target shape.

[INFERRED] The title and headline conclusion outrun the evidence. The study shows that one confounded, segmenter-shaped implementation did not improve over RANDOM in one run. It does not isolate anatomical precision or show that location beats shape.

## “The best policy consults no segmentation model”

[MEASURED] At epoch 100, CENTROID has AUC 0.8855 and exceeds ENVELOPE by +0.0047 with interval [+0.0004, +0.0091]. The two are not separated at epochs 50 or 75.

[INFERRED] Calling CENTROID the best observed epoch-100 arm is fair. Calling it the best policy generally is not established without repeated pretraining and complete long-horizon results for the anatomy arms.

## “Fraction of anatomy hidden is uncorrelated with downstream AUC”

[MEASURED] The reported Spearman coefficient is 0.00 over four rectangle policies, with the paper stating that the association is not significant.

[INFERRED] This supports only a descriptive statement about four arm-level points. It is not persuasive evidence that anatomy coverage and downstream quality are generally unrelated.

## COVER degradation

[MEASURED] Where the epoch-100 result is presented as valid, the implemented COVER arm ends −0.0168 below RANDOM.

[INFERRED] That trajectory cannot be attributed to excessive anatomical coverage, which the paper correctly acknowledges. Because the PDF contradicts itself about whether the endpoint exists or remains pending, even the narrower implemented-policy claim is not reliably documented.

## Subgroup claims

[MEASURED] Every reported disease-severity stratum has a positive RANDOM-to-CENTROID interval excluding zero.

[INFERRED] The statement that every severity stratum improved is supported for the fixed score vectors. The statement or implication that mild disease benefits more is not supported because differences between severity gains were not tested.

[MEASURED] Race gains are positive in point estimate, but the black and Asian intervals include zero.

[INFERRED] The paper generally calibrates this race result appropriately.

## Operating-point claim

[MEASURED] At the validation target specificity of 0.90, RANDOM achieves test specificity 0.8794 and CENTROID achieves 0.8696.

[MEASURED] The paper nevertheless interprets the sensitivity difference as “two to three more cases detected per hundred at the same false-positive rate.”

[INFERRED] The false-positive rates are not the same on the test set. The sensitivity comparison is meaningful at separately validation-selected thresholds, but the quoted same-rate clinical interpretation is not supported.

# 5. SELF-REPORTED DEFECTS

## Why the disclosure increases trust

[MEASURED] The paper identifies the exact failure mechanism: targets are truncated to the shortest target in a microbatch after COVER has optimized their placement.

[MEASURED] It quantifies intended and delivered coverage, target deformation, directional top bias, and the effect on ENVELOPE and the anatomy-family comparison.

[MEASURED] It explicitly withdraws the conclusion that aggressive coverage is harmful and states that a corrected arm must be retrained from the common ancestor.

[INFERRED] This is unusually candid. The authors distinguish an observed trajectory from the intended intervention and do not conceal an unfavorable engineering finding.

## Why it decreases confidence

[MEASURED] The instrumentation recorded coverage before truncation, so every training log reported the intended behavior rather than the actual masks.

[MEASURED] The defect was discovered only after the purported epoch-100 result. ENVELOPE shares the directional clipping path, ANATOMY-V2 later underwent a target-precision splice, probe precision differed across families, and several earlier runs were retracted or excluded.

[INFERRED] These are not isolated cosmetic errors. They show that delivered treatments and numerical protocols were not validated before expensive training and analysis. The contradictory COVER timeline further suggests that the final manuscript was assembled from inconsistent experimental states.

## What remains valid

[INFERRED] The observed RANDOM, ENVELOPE, and CENTROID score comparisons remain interpretable as single-run comparisons of the implemented rectangle-family policies, because the paper states that they share the same collation path.

[INFERRED] ANATOMY-V2’s epoch-50 score remains an observation about that implemented arm, but it cannot identify an effect of shape or anatomical precision because multiple delivered properties differ simultaneously.

[INFERRED] COVER does not test aggressive coverage. Its implemented trajectory could remain a valid observation only if the later checkpoints and probes actually exist and are valid.

[INFERRED] Because the PDF simultaneously calls those later probes reported and pending, the disclosure is not complete enough to determine exactly which COVER results remain admissible.

[INFERRED] Overall, the disclosure increases trust in the authors’ willingness to report problems but decreases trust in the experimental infrastructure and in this PDF as the authoritative record.

# 6. RED FLAGS

1. [MEASURED] The supposedly held-out test split was repeatedly inspected, and policies, checkpoints, and analyses were selected after that inspection.  
   [INFERRED] The test set functioned as a development set at the research-program level. The reported intervals and multiplicity corrections do not account for this adaptivity.

2. [MEASURED] The manuscript presents incompatible accounts of COVER’s stopping point and endpoint validity.  
   [INFERRED] This is the largest auditability red flag because the abstract promotes the disputed endpoint.

3. [MEASURED] The paper says the generation pipeline prevents prose-table disagreement, yet the PDF contains multiple such disagreements.  
   [INFERRED] This suggests stale prose or partially updated generated content.

4. [MEASURED] CENTROID becomes INTENSITY in Table 8, and retracted runs are called coverage probes in prose but RANDOM in the inventory.  
   [INFERRED] These unexplained identity changes make it difficult to track which predictions belong to which intervention.

5. [MEASURED] The paper identifies the missing arm needed to distinguish CENTROID’s possible mechanisms: a vertically randomized band with area and context held fixed.  
   [INFERRED] Without that baseline, the proposed “consistency of location” mechanism is speculative.

6. [MEASURED] The direction of the overall finding is explicitly described as not new in Appendix K.  
   [INFERRED] Novelty therefore depends heavily on the controlled nature of the comparison, precisely where the central anatomy-versus-rectangle design is confounded.

# 7. WEAKNESSES AND LIMITATIONS

1. **Central causal contrast is not identified.**  
   [INFERRED] Shape and anatomical precision are inseparable from mask ratio, context size, loss slots, and collation. The title asserts a comparison the experiment does not provide.

2. **No pretraining replication.**  
   [MEASURED] Every masking policy was pretrained once.  
   [INFERRED] Test-subject bootstraps cannot establish that differences are policy effects rather than stochastic continuation effects.

3. **Adaptive reuse of the test set.**  
   [MEASURED] Policies, checkpoints, and analyses were chosen after repeated inspection of the same test split.  
   [INFERRED] This substantially weakens all nominal inference, including subgroup and operating-point analyses.

4. **H2 lacks its required direct contrast.**  
   [INFERRED] The transitive-null argument is invalid, and ANATOMY-V1 is unavailable at the central matched epoch.

5. **Experimental-state and reporting inconsistencies.**  
   [INFERRED] The COVER timeline, precision caption, arm identities, probe counts, and subgroup statements do not form one coherent final record.

6. **Narrow external validity.**  
   [MEASURED] The study uses one OCT dataset, one glaucoma task, one segmentation model, and predominantly frozen mean-pool probes.  
   [INFERRED] It cannot support broad conclusions about anatomy-guided medical pretraining.

7. **Weak mechanism analysis.**  
   [MEASURED] The mask-geometry association uses four rectangle policies and is explicitly nonsignificant.  
   [INFERRED] This is insufficient to distinguish anatomical targeting, spatial consistency, masking difficulty, and delivered context.

8. **Secondary subgroup analyses are underpowered and exploratory.**  
   [MEASURED] Several subgroup intervals include zero, checkpoints are correlated within branches, and no pretraining replication is available.  
   [INFERRED] These analyses should remain ancillary and should not strengthen the acceptance case.

# 8. VERDICT

**Accept probability:** [INFERRED] 15%

**Meta-review:** [INFERRED] This is a potentially useful and commendably candid negative study, but its central conclusion is not supported by the experimental design. The paper directly supports a narrower observation: in one continuation per policy, two simple location-biased rectangle samplers produced better fixed-test predictions than RANDOM, while one substantially different segmenter-shaped treatment did not. It does not establish that location beats shape or that anatomical precision fails, because the relevant arms differ simultaneously in mask ratio, context, loss slots, and collation, and H2 is never directly tested. Single-run pretraining, acknowledged adaptive reuse of the test set, and serious contradictions about the defective COVER arm further prevent reliable inference. The current PDF is therefore below the bar for acceptance despite the value of the question and the transparency of several limitations.

**Single highest-value change before the deadline:** [INFERRED] Replace the confounded centerpiece with a direct, paired location-versus-shape experiment that holds delivered mask ratio, context size, loss slots, and collation fixed, repeats continuation from the shared checkpoint, and reports the direct paired contrast. If that experiment cannot be completed, the title and conclusions should be narrowed to a single-run observational comparison of the implemented policies.